related with hypercytokinemia [5]. Whether antiviral treatment for these patients will provide benefit is not yet clear. More studies on viral load profiles among hospitalized patients with influenza and clinical trials of late antiviral therapy are needed to resolve the issue.

Acknowledgments

Potential conflicts of interest. All authors: no conflicts.


Departments of Medicine and Therapeutics and *Microbiology, The Chinese University of Hong Kong, Hong Kong

References


Reprints or correspondence: Dr. Nelson Lee, Div. of Infectious Diseases, Dept. of Medicine and Therapeutics, The Chinese University of Hong Kong, 9/F, Clinical Sciences Bldg., Prince of Wales Hospital, Shatin, Hong Kong Special Administrative Region, People’s Republic of China (leelsn@cuhk.edu.hk).

Clinical Infectious Diseases 2008;46:1323–4
© 2008 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2008/4608-0033S15.00
DOI: 10.1086/533477

Increased Antimicrobial Susceptibility Profiles among Polymyxin-Resistant Acinetobacter baumannii Clinical Isolates

To the Editor—We read with great interest the article by Li et al. [1], in which the authors reported promising therapeutic options for treatment of infections caused by colistin-resistant *Acinetobacter baumannii*. The authors observed overall increased antimicrobial susceptibility among colistin-resistant strains, compared with the parent colistin-susceptible strains. Because of the potential therapeutic importance of this observation, we evaluated the susceptibility profiles of polymyxin-resistant and -susceptible *A. baumannii* clinical isolates collected as part of the global SENTRY Antimicrobial Surveillance Program during the period 2001–2007 [2].

A collection of 3707 *A. baumannii* isolates were tested for susceptibility to numerous antimicrobial agents using validated broth microdilution panels with cation-adjusted Mueller–Hinton medium (TREK Diagnostics) [3]. Testing and incubation were performed according to the methods of the Clinical and Laboratory Standards Institute [4]. MICs were interpreted as specified by the Clinical and Laboratory Standards Institute [5], except for tigecycline MICs, which were interpreted according to breakpoints approved by the US Food and Drug Administration (breakpoint for susceptibility, ≤2 μg/mL; breakpoint for resistance, >8 μg/mL). For comparison purposes, geographically unrelated polymyxin-resistant isolates were included in this study, and the resistance phenotype was confirmed by Etest (AB Biodisk). Susceptibility rates for polymyxin-resistant isolates were compared with those for polymyxin-susceptible isolates by χ² test, using EpInfo, version 3.4.1 (Centers for Disease Control and Prevention). *P* < .05 was considered to be statistically significant.

The distribution of MIC₉₀ and susceptibility rates among polymyxin-resistant and -susceptible *A. baumannii* for selected antimicrobial agents are shown in table 1. Most drugs demonstrated limited spectrums of activity against the polymyxin-susceptible group (susceptibility rate, ≤53.8%), except for the carbapenems (imipenem [71.6% susceptible] and meropenem [68.0% susceptible]), tetracyclines (doxycycline [74.6% susceptible], minocycline [88.4% susceptible], and tigecycline [97.0% inhibited at ≤2 μg/mL]). Overall, compared with the polymyxin-susceptible group, the polymyxin-resistant group showed higher susceptibility rates for the majority of antimicrobial agents (16 of 22 antimicrobial agents). The differences were mostly observed among those drugs showing lower susceptibility rates (<48.8%) and were statistically significant for the β-lactams ampicillin-sulbactam, aztreonam, cefoxitin, cefepime, ceftriaxone, and cefturoxime (*P* < .05). In contrast, antimicrobial agents with better activity, such as imipenem, meropenem, tobramycin, minocycline, and tigecycline, showed similar or slightly higher activity against the polymyxin-susceptible isolates, compared with the polymyxin-resistant isolates.

Overall, these results corroborate with those previously reported by Li et al. [1], except for the results for ticarcillin-clavulanate and carbapenems, for which the authors noted substantially lower MICs among the colistin-resistant group, compared with the colistin-susceptible group. On the other hand, compared with our group of polymyxin-susceptible isolates, our collection of polymyxin-resistant clinical isolates showed higher susceptibility rates for amikacin, tetracycline, and trimethoprim-sulfamethoxazole—results not observed previously by Li et al. [1].

Li et al. suggested that *A. baumannii* showing phenotypic resistance to colistin may possess outer-membrane modifications, consequently increasing permeability for antimicrobial agents, which may also explain the results obtained in our study. Regardless of the changes, they were not favorable for those antimicrobial agents frequently used for treatment of infections caused by multidrug-resistant *A. baumannii*, such as the carbapenems and tobramycin. Furthermore, minocycline and the novel glycyclline tigecycline, which may represent a valuable antimicrobial for treatment of infections caused by multidrug-resistant *A. baumannii* [6], were highly active independently of the polymyxin susceptibility profile.
In addition, it is important to mention that other resistance mechanisms were present among the polymyxin-resistant isolates when the antimicrobial agents did not become satisfactorily more active; however, the susceptibility rate for ampicillin-sulbactam increased substantially among those isolates (from 45.4% to 70.8%) (table 1). In summary, this study complements the data reported previously [1], providing additional insights for combination therapeutic options and for possible novel antimicrobial agents in development, and indicates that local susceptibility testing results will be important in guiding treatment.

**Acknowledgments**

**Potential conflicts of interest.** R.N.J., T.R.F., and H.S.S. have received research and/or education grants from AB Biodisk, Abbott, API, Arpida, Astellas, AstraZeneca, Avea, Bayer, bioMérieux, Cadence, Cempra, Cereza, Chiron, Cornerstone, Cubist, Daiichi, Elan, Elanco, Enanta, GlaxoSmithKline, Johnson & Johnson (Ortho McNeil), Merck, Novartis, Optimer, Ordway, Osmotics, Pacific Beach, Peninsula, Pfizer, Protez, Replidyne, Schering-Plough, Sequoia, Shionogi, Theravance, TREK Diagnostics, ViroPharma, and Wyeth. R.E.M.: no conflicts.

Rodrigo E. Mendes,1 Thomas R. Fritsche,1 Helio S. Sader,1,2 and Ronald N. Jones1,3

1JMI Laboratories, North Liberty, Iowa; 2Universidade Federal de São Paulo, São Paulo, Brazil; and 3Tufts University School of Medicine, Boston, Massachusetts

**References**


**CORRESPONDENCE • CID 2008:46 (15 April) • 1325**


Reprints or correspondence: Dr. Rodrigo E. Mendes, JMI Laboratories, 345 Beaver Creek Centre, Ste. A, North Liberty, IA 52317 (rodrigo-mendes@jmilabs.com).

Clinical Infectious Diseases 2008;46:1324-6
© 2008 by the Infectious Diseases Society of America. All rights reserved. 1058-4838/2008/4608-0034$15.00
DOI: 10.1086/533476